<DOC>
	<DOCNO>NCT01345006</DOCNO>
	<brief_summary>This safety tolerability trial evaluate effect subretinal injection human embryonic stem cell derive retinal pigment epithelium cell patient Stargardt 's Macular Dystrophy ( SMD ) .</brief_summary>
	<brief_title>Sub-retinal Transplantation hESC Derived RPE ( MA09-hRPE ) Cells Patients With Stargardt 's Macular Dystrophy</brief_title>
	<detailed_description>This study Phase I/II , open-label , non randomize , sequential , multi-center clinical trial . There 5 cohort , 4 low vision cohort contain 3 patient , good vision cohort contain 4 patient . The enrolled cohort follow : Three SMD patients- 50,000 MA09-hRPE cell transplant Three SMD patients- 100,000 MA09-hRPE cell transplant Four Better Vison SMD patients- 100,000 MA09-hRPE cell transplant Three SMD patients- 150,000 MA09-hRPE cell transplant Three SMD patients- 200,000 MA09-hRPE cell transplant Patients enrol sequentially , within cohort 3 patient , patient 's clinical course first 6 week follow cell transplantation review independent ( DSMB ) enrollment open next 2 patient . A full safety assessment 3 patient cohort make DSMB 3rd patient cohort complete 4 week follow-up , first patient next cohort receive cell transplant . The exception good vision group patient may enrol DSMB approval receive . Each cohort enrol sequentially turn , exception well vision cohort may enrol parallel cohort . The day cell implantation Day 0 , patient remain study last visit 12 month .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Adult male female 18 year age . Clinical diagnosis advance SMD . If know , patient 's genotype record medical history , unknown , patient allow submission sample genotyping.Clinical finding consistent SMD . The visual acuity eye receive transplant well 20/400 . The visual acuity eye good vision cohort receive transplant well 20/100 . The visual acuity eye receive transplant well 20/400 bad vision patient worse 20/100 good vision patient . Peripheral visual field constriction document standard kinetic visual field test . Electrophysiological finding consistent SMD . Medically suitable undergo vitrectomy subretinal injection . Medically suitable general anesthesia wake sedation , need . Medically suitable transplantation embryonic stem cell line : Normal serum chemistry ( sequential multichannel analyzer 20 [ SMA 20 ] ) hematology ( complete blood count [ CBC ] , prothrombin time [ PT ] , activate partial thromboplastin time [ aPTT ] ) screening test . Negative urine screen drug abuse . Negative human immunodeficiency virus ( HIV ) , hepatitis B ( HBV ) , hepatitis C ( HCV ) serology . No history malignancy , exception successfully treat basal cell squamous cell carcinoma skin . Negative cancer screen within previous 6 month : complete history &amp; physical examination ; dermatological screening exam malignant lesion ; negative fecal occult blood test &amp; age 50 year , negative colonoscopy within previous 7 year ; negative chest roentgenogram ( CXR ) ; normal CBC &amp; manual differential ; negative urinalysis ( U/A ) ; normal thyroid exam ; male , normal testicular examination ; age 40 , digital rectal examination ( DRE ) prostate specific antigen ( PSA ) ; female , normal pelvic examination Papanicolaou smear ; female , normal clinical breast exam 40 year age old , negative mammogram . If female childbearing potential , willing use two effective form birth control study . If male , willing use barrier spermicide contraception study . Willing defer future blood , blood component tissue donation . Able understand willing sign inform consent . History malignancy , exception successfully treat basal cell squamous cell carcinoma skin . History myocardial infarction previous 12 month . History diabetes mellitus . Any immunodeficiency . Any current immunosuppressive therapy intermittent low dose corticosteroid . Serologic evidence infection Hepatitis B , Hepatitis C , HIV . Current participation clinical trial . Participation within previous 6 month clinical trial drug ocular systemic administration . Any sightthreatening ocular disease . Any chronic ocular medication . Any history retinal vascular disease ( compromised bloodretinal barrier . Glaucoma . Uveitis intraocular inflammatory disease . Significant lens opacity medium opacity . Ocular lens removal within previous 3 month . If female , pregnancy lactation . Any medical condition , , Investigator 's judgment , interfere patient 's ability comply protocol , compromise patient safety , interfere interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>juvenile macular dystrophy</keyword>
	<keyword>SMD</keyword>
	<keyword>fundus flavimaculatus</keyword>
</DOC>